Table 2 Cardiologic and respiratory therapy at baseline and after 6 months of treatment (all p = not significant)
Baseline (%) | 6 months (%) | |
|---|---|---|
Cardiologic therapy | ||
ACE inhibitors | 27 | 29 |
ARBs | 34 | 32 |
Beta-blockers | 82 | 79 |
Ivabradine | 9 | 9 |
Digitalis | 14 | 14 |
Diuretics | 95 | 93 |
MRAs | 57 | 57 |
Ca channel blockers | 18 | 16 |
Statins | 36 | 41 |
Antiplatelet | 63 | 63 |
Anticoagulant | 45 | 45 |
Respiratory therapy | ||
No therapy | 11 | 0 |
Titropium | 39 | 0 |
Glycopyrronium | 21 | 0 |
Aclidinium | 1 | 0 |
Indacaterol | 4 | 0 |
Salmeterol/fluticasone 50/250 μg | 1 | 0 |
Salmeterol/fluticasone 50/500 μg | 3 | 0 |
Fluticasone/vilanterol | 13 | 0 |
Budesonide/formeterol | 1 | 0 |
Tiotropio/budesonide/formeterol | 4 | 0 |
Tiotropio/salmeterol/fluticasone | 1 | 0 |
Aclidinium/fluticasone/vilanterol/theopylline | 1 | 0 |